Moreover, CAdTrio not only expressed cytokines (IL-12) and immune checkpoint blockers (PD-L1Ab) but also integrated the oncolytic adenovirus targeting CD44 variant 6 (CD44v6)-specific BiTE, which was combined with HER2-specific CAR-T cells to improve tumor control significantly [210]. This evidence concerns the gene ERBB2 and neoplasm.